AIMC Topic: Receptor, Transforming Growth Factor-beta Type I

Clear Filters Showing 1 to 2 of 2 articles

Artificial intelligence-driven discovery of YH395A: A novel TGFβR1 inhibitor with potent anti-tumor activity against triple-negative breast cancer.

Cell communication and signaling : CCS Jul 8, 2025
Characterized by high malignancy and limited treatment efficacy, triple-negative breast cancer (TNBC) remains a clinically challenging subtype within breast cancer classifications, marked by rapid progression and high mortality. Abnormal activation o...
Humans Artificial Intelligence Female Animals Drug Discovery Antineoplastic Agents Cell Line, Tumor Mice Triple Negative Breast Neoplasms Cell Proliferation Cell Movement Mice, Nude Xenograft Model Antitumor Assays Carbolines Receptor, Transforming Growth Factor-beta Type I
View on PubMed DOI

Evaluating Deep Learning models for predicting ALK-5 inhibition.

PloS one Jan 28, 2021
Computational methods have been widely used in drug design. The recent developments in machine learning techniques and the ever-growing chemical and biological databases are fertile ground for discoveries in this area. In this study, we evaluated the...
Humans Deep Learning Computational Biology Models, Chemical Drug Evaluation, Preclinical Protein Kinase Inhibitors Receptor, Transforming Growth Factor-beta Type I
View on PubMed DOI
Popular Topics
Recent Journals